| Literature DB >> 35051237 |
Noori Akhtar-Danesh1,2, Andrea Baumann3, Mary Crea-Arsenio3, Valentina Antonipillai3.
Abstract
The coronavirus disease 2019 (COVID-19) has had devastating consequences worldwide, including a spike in global mortality. Residents of long-term care homes have been disproportionately affected. We conducted a retrospective cohort study to determine the scale of pandemic-related deaths of long-term care residents in the province of Ontario, Canada, and to estimate excess mortality due to a positive COVID-19 test adjusted for demographics and regional variations. Crude mortality rates for 2019 and 2020 were compared, as were predictors of mortality among residents with positive and negative tests from March 2020 to December 2020. We found the crude mortality rates were higher from April 2020 to June 2020 and from November 2020 to December 2020, corresponding to Wave 1 and Wave 2 of the pandemic in Ontario. There were also substantial increases in mortality among residents with a positive COVID-19 test. The significant differences in excess mortality observed in relation to long-term care home ownership category and geographic region may indicate gaps in the healthcare system that warrant attention from policymakers. Further investigation is needed to identify the most relevant factors in explaining these differences.Entities:
Mesh:
Year: 2022 PMID: 35051237 PMCID: PMC8775534 DOI: 10.1371/journal.pone.0262807
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Crude mortality rate based on year and COVID-19 test result.
Distribution, n (%), of COVID-19 tests based on demographics from March 2020 to December 2020.
| Category | Negative Test | Positive Test | Total | P-value |
|---|---|---|---|---|
|
| ||||
| Male | 20,586 (87.0) | 3082 (13.0) | 23,668 | 0.002 |
| Female | 45,150 (87.8) | 6282 (12.2) | 51,432 | - |
|
| ||||
| 65–69 years | 3679 (86.4) | 579 (13.6) | 4285 | 0.001 |
| 70–74 years | 5689 (86.7) | 872 (13.3) | 6561 | - |
| 75–79 years | 8413 (87.4) | 1211 (12.6) | 9624 | - |
| 80–84 years | 12,476 (87.1) | 1844 (12.9) | 14,320 | - |
| ≥85 years | 35,479 (88.0) | 4858 (12.0) | 40,337 | - |
| 84.3 (8.2) | 83.8 (8.2) | 84.3 (8.2) | <0.001 | |
| 0.72 (0.83) | 0.60 (0.76) | 0.71 (0.83) | <0.001 | |
|
| ||||
| Central | 15,662 (76.6) | 4793 (23.4) | 20,455 | <0.001 |
| Southwest | 23,251 (92.3) | 1932 (7.7) | 25,183 | - |
| East | 17,492 (87.7) | 2453 (12.3) | 19,945 | - |
| North | 9287 (98.2) | 174 (1.8) | 9461 | - |
|
| ||||
| 1 (lowest) | 19,946 (87.5) | 2796 (12.5) | 22,292 | <0.001 |
| 2 | 13,917 (85.6) | 2333 (14.4) | 16,250 | - |
| 3 | 11,824 (87.6) | 1677 (12.4) | 13,501 | - |
| 4 | 10,940 (89.5) | 1284 (10.5) | 12,224 | - |
| 5 (highest) | 9029 (88.4) | 1183 (11.6) | 10,212 | - |
|
| ||||
| Robust | 8518 (87.6) | 1205 (12.4) | 9723 | <0.001 |
| Pre-frail | 21,666 (86.5) | 3381 (13.5) | 25,047 | - |
| Frail | 34,963 (88.1) | 4737 (11.9) | 39,700 | - |
|
| ||||
| Municipal | 14,822 (94.6) | 850 (5.4) | 15,672 | <0.001 |
| Non-profit | 18,225 (90.0) | 2027 (10.0) | 20,252 | - |
| Private | 32,672 (83.4) | 6487 (16.6) | 39,159 | - |
|
|
|
|
| - |
aChanges in Health, End-stage disease and Symptoms and Signs.
Mortality rate (%) based on COVID-19 tests and demographics for March 2020 to December 2020.
| Category | Negative Test | Positive Test | Total | |||
|---|---|---|---|---|---|---|
| Mortality rate | P-value | Mortality rate | P-value | Mortality rate | P-value | |
|
| ||||||
| Male | 5.76 | <0.001 | 32.18 | <0.001 | 9.13 | <0.001 |
| Female | 4.18 | - | 21.27 | - | 6.24 | - |
|
| ||||||
| 65–69 years | 3.06 | - | 15.09 | - | 4.67 | - |
| 70–74 years | 3.59 | - | 17.76 | - | 5.45 | - |
| 75–79 years | 3.90 | <0.001 | 19.62 | <0.001 | 5.87 | <0.001 |
| 80–84 years | 4.22 | - | 23.94 | - | 6.71 | - |
| ≥85 years | 5.36 | - | 28.90 | - | 8.14 | - |
|
| ||||||
| Central | 5.38 | - | 23.59 | - | 9.60 | - |
| Southwest | 4.44 | <0.001 | 21.18 | <0.001 | 5.67 | <0.001 |
| East | 4.78 | - | 30.49 | - | 7.91 | - |
| North | 3.88 | - | 19.05 | - | 4.16 | - |
|
| ||||||
| 1 (lowest) | 4.69 | - | 24.51 | - | 7.14 | - |
| 2 | 4.81 | - | 26.35 | - | 7.88 | - |
| 3 | 4.41 | 0.098 | 25.34 | 0.244 | 6.96 | <0.001 |
| 4 | 4.40 | - | 23.61 | - | 6.37 | - |
| 5 (highest) | 5.11 | - | 23.36 | - | 7.17 | - |
|
| ||||||
| Robust | 2.41 | - | 16.75 | - | 4.19 | - |
| Pre-frail | 3.74 | <0.001 | 21.61 | <0.001 | 6.12 | <0.001 |
| Frail | 5.72 | - | 29.20 | - | 8.47 | - |
|
| ||||||
| Municipal | 4.27 | - | 22.45 | - | 5.23 | - |
| Non-profit | 4.43 | <0.001 | 23.48 | 0.044 | 6.32 | <0.001 |
| Private | 5.00 | - | 25.58 | - | 8.36 | - |
Predictors of death within 30 Days after COVID-19 test.
| Variable | HR | P-value |
|---|---|---|
| Region, COVID-19 test result | ||
| Central, negative | Reference group | - |
| Central, positive | 5.27 (4.81, 5.78) | <0.001 |
| Southwest, negative | 0.77 (0.70, 0.84) | <0.001 |
| Southwest, positive | 5.64 (5.00, 6.39) | <0.001 |
| East, negative | 0.86 (0.78, 0.94) | 0.002 |
| East, positive | 6.90 (6.24, 7.64) | <0.001 |
| North, negative | 0.73 (0.64, 0.82) | <0.001 |
| North, positive | 4.73 (3.32, 6.75) | <0.001 |
|
| 1.06 (1.03, 1.08) | <0.001 |
|
| ||
| Male | Reference group | - |
| Female | 0.58 (0.55, 0.62) | <0.001 |
|
| ||
| 65–69 years | Reference group | - |
| 70–74 years | 1.16 (0.97, 1.38) | 0.105 |
| 75–79 years | 1.33 (1.12, 1.57) | 0.001 |
| 80–84 years | 1.53 (1.31, 1.79) | <0.001 |
| ≥85 years | 2.00 (1.73, 2.32) | <0.001 |
| 1.13 (1.09, 1.16) | <0.001 | |
|
| ||
| Robust | Reference group | - |
| Pre-frail | 1.44 (1.29, 1.61) | <0.001 |
| Frail | 2.06 (1.85, 2.29) | <0.001 |
|
| ||
| Municipal | Reference group | - |
| Non-profit | 1.06 (0.97, 1.16) | 0.235 |
| Private | 1.25 (1.16, 1.35) | <0.001 |
aHazard rate.
bChanges in Health, End-stage disease and Symptoms and Signs.
Fig 2Adjusted mortality rate based on region and COVID-19 test result adjusted for sex, age group, Changes in Health, End-stage disease and Symptoms and Signs (CHESS) scale, frailty, and long-term care home ownership.
Fig 3Excess mortality rate due to a positive COVID-19 test, adjusted for sex, age group, Changes in Health, End-stage disease and Symptoms and Signs (CHESS) scale, frailty, and long-term care home ownership.